TY - JOUR
T1 - Preoperative chemoradiation in rectal cancer
T2 - Retrospective comparison between capecitabine and continuous infusion of 5-fluorouracil
AU - Yerushalmi, Rinat
AU - Idelevich, Efraim
AU - Dror, Ygael
AU - Stemmer, Salomon M.
AU - Figer, Arie
AU - Sulkes, Aaron
AU - Brenner, Baruch
AU - Loven, David
AU - Dreznik, Zeev
AU - Nudelman, Israel
AU - Shani, Adi
AU - Fenig, Eyal
PY - 2006/6/1
Y1 - 2006/6/1
N2 - Background: We compared the efficacy and toxicity of oral capecitabine and continuous infusion of 5-fluorouracil (5-FU) in the preoperative chemoradiation treatment of patients with rectal cancer. Patients and Methods: The files of 89 patients with rectal cancer, 43 treated preoperatively with oral capecitabine and 46 with intravenous 5-FU, were reviewed, and the outcome of the groups was compared. Results: There was no statistically significant difference in the complete pathological response rate between the capecitabine and the 5-FU groups (30% vs. 17%, P = 0.15). The downstaging rate was higher in the capecitabine group (77% vs. 50%, P = 0.009). Toxicity was mild in both groups. The rate of Grade 3 gastrointestinal toxicity was similar in the two groups (diarrhea 2% vs. 4%, proctitis 5% vs. 7%), except for one patient in the 5-FU group (2%) who developed a recto vaginal fistula. In the capecitabine group, one patient (2%) had Grade 3 hand-foot syndrome, and another had an acute myocardial infarction. In the 5-FU group, two patients (4%) had Grade 3 hematological toxicity, and three (6%) had complications from Port-a-Cath insertion. Conclusion: Preoperative chemoradiation with oral capecitabine appears to be safe and well tolerated, and at least as good as continuous 5-FU.
AB - Background: We compared the efficacy and toxicity of oral capecitabine and continuous infusion of 5-fluorouracil (5-FU) in the preoperative chemoradiation treatment of patients with rectal cancer. Patients and Methods: The files of 89 patients with rectal cancer, 43 treated preoperatively with oral capecitabine and 46 with intravenous 5-FU, were reviewed, and the outcome of the groups was compared. Results: There was no statistically significant difference in the complete pathological response rate between the capecitabine and the 5-FU groups (30% vs. 17%, P = 0.15). The downstaging rate was higher in the capecitabine group (77% vs. 50%, P = 0.009). Toxicity was mild in both groups. The rate of Grade 3 gastrointestinal toxicity was similar in the two groups (diarrhea 2% vs. 4%, proctitis 5% vs. 7%), except for one patient in the 5-FU group (2%) who developed a recto vaginal fistula. In the capecitabine group, one patient (2%) had Grade 3 hand-foot syndrome, and another had an acute myocardial infarction. In the 5-FU group, two patients (4%) had Grade 3 hematological toxicity, and three (6%) had complications from Port-a-Cath insertion. Conclusion: Preoperative chemoradiation with oral capecitabine appears to be safe and well tolerated, and at least as good as continuous 5-FU.
KW - Capecitabine
KW - Continuous-infusion 5-FU
KW - Preoperative chemoradiation
KW - Rectal cancer
UR - http://www.scopus.com/inward/record.url?scp=33744472470&partnerID=8YFLogxK
U2 - 10.1002/jso.20503
DO - 10.1002/jso.20503
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
AN - SCOPUS:33744472470
SN - 0022-4790
VL - 93
SP - 529
EP - 533
JO - Journal of Surgical Oncology
JF - Journal of Surgical Oncology
IS - 7
ER -